BTG plc (BTG) Earns Hold Rating from Numis Securities Ltd
BTG plc (LON:BTG)‘s stock had its “hold” rating reiterated by investment analysts at Numis Securities Ltd in a research note issued to investors on Thursday. They currently have a GBX 737 ($9.62) price target on the stock. Numis Securities Ltd’s price target suggests a potential upside of 13.91% from the company’s current price.
Other equities analysts have also issued reports about the company. Deutsche Bank AG increased their price objective on BTG plc from GBX 740 ($9.66) to GBX 840 ($10.96) and gave the company a “buy” rating in a research report on Tuesday, July 12th. JPMorgan Chase & Co. reduced their price objective on BTG plc from GBX 800 ($10.44) to GBX 790 ($10.31) and set a “neutral” rating on the stock in a research report on Friday, July 15th. Jefferies Group reiterated a “buy” rating and set a GBX 860 ($11.23) price objective on shares of BTG plc in a research report on Friday, July 15th. Royal Bank Of Canada increased their price objective on BTG plc from GBX 820 ($10.70) to GBX 890 ($11.62) and gave the company an “outperform” rating in a research report on Wednesday, June 8th. Finally, Stifel Nicolaus reiterated a “buy” rating on shares of BTG plc in a research report on Friday, June 24th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of GBX 781 ($10.19).
Shares of BTG plc (LON:BTG) opened at 665.00 on Thursday. The company’s market capitalization is GBX 2.55 billion. The firm has a 50-day moving average price of GBX 626.72 and a 200-day moving average price of GBX 640.49. BTG plc has a one year low of GBX 504.00 and a one year high of GBX 739.50.
In other BTG plc news, insider Soderstrom,Rolf sold 74,327 shares of the stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.82), for a total value of £502,450.52 ($655,855.01).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.